This is in line with recent observations that monoclonal antibodies blocking the fibronectin binding site do not abolish high affinity binding of TG2 to select tissues [50], as well as a report showing TG2 uptake by GPR56-expressing tumour cells [35]. This evidence concerns the gene TGM2 and neoplasm.